hydrocodone/paracetamol / Generic mfg. - LARVOL DELTA

Clinical Efficacy and Safety Profile of Suzetrigine: A Novel Non-opioid Analgesic Targeting NaV1.8 Sodium Channel. (PubMed, Cureus) - "Suzetrigine exhibits high selectivity for the NaV1.8 channel through a novel allosteric mechanism with significant pain relief compared to placebo and comparable efficacy to a standard hydrocodone/acetaminophen combination. Its recent approval by the U.S. Food and Drug Administration for moderate to severe acute pain underscores its potential as an effective non-opioid therapeutic. While its short-term efficacy and safety are well established, future research should focus on its long-term safety profile and its utility across a broader range of pain conditions."

Journal • Review • Addiction (Opioid and Alcohol) • CNS Disorders • Pain • Psychiatry • NAV1

Postoperative Pain Management in Rhinoplasty (clinicaltrials.gov) - P2 | N=159 | Completed | Sponsor: Stanford University | Active, not recruiting ➔ Completed

Trial completion • Aesthetic Medicine • Pain

Treatment of Acute Postoperative Pain in Chronic Pain Patient Using Suzetrigine, a Novel Non-Opioid Analgesic (ASRA-FALL 2025) - "Trials have shown that it reduces moderate-to-severe acute pain comparably to hydrocodone/acetaminophen (Bertoch, 2025). We present a case of acute postoperative pain in a chronic pain patient with bilateral above-knee amputations (AKAs) who responded well to suzetrigine."

Clinical • Pain

A Rare Manifestation of Immune Checkpoint Inhibitor Toxicity (ACG 2025) - "Their use has significantly increased since ipilimumab was approved in 2011 for metastatic melanoma...We present a case of immune-mediated cholangitis (IMC) induced by ICI.Case Description/ An 80-year-old female with metastatic endometrial cancer presented to the emergency department with encephalopathy due to hydrocodone-acetaminophen taken for cancer-related pain. She took a 1-week course of trimethoprim-sulfamethoxazole (TMP-SMX) and completed pembrolizumab cycle 19 3 weeks prior to presentation...N-acetylcysteine and antibiotics were prescribed on admission...There are some data to suggest ursodiol may provide added benefit. Further research is necessary to provide diagnostic and management guidance. Figure: CT with contrast demonstrating bile duct thickeningFigure: ALP trend following initiation of glucocorticoids on Day 2"

Checkpoint inhibition • CNS Disorders • Endometrial Cancer • Gastrointestinal Disorder • Hepatology • Immunology • Melanoma • Oncology • Solid Tumor

Beyond Opioids: A Review of Suzetrigine for Acute Pain Management. (PubMed, Int J Mol Sci) - "However, suzetrigine appears less potent than hydrocodone-acetaminophen in this context, and it remains unclear how effective suzetrigine is in treating more severe postoperative pain. Notably, all current studies are limited to short durations of treatment; further studies will be required to delineate suzetrigine's long-term efficacy, safety, and addiction potential to be utilized in the management of chronic pain patients. This article provides a review of the current literature available on the use of suzetrigine in treating acute pain."

Journal • Review • Addiction (Opioid and Alcohol) • CNS Disorders • Pain • Psychiatry • NAV1

Efficacy of Methylprednisolone for Pain Control After ACL Repair (clinicaltrials.gov) - P4 | N=90 | Recruiting | Sponsor: St. Louis University | Enrolling by invitation ➔ Recruiting

Enrollment status • Pain

Effect of Regional Anesthesia on Discharge Opioids After Pediatric Sclerotherapy: A Follow Up Study (ASA 2025) - "309 patients were included in final analysis. 157 patients (50.8%) received opioids at discharge, primarily hydrocodone-acetaminophen (98.8%). Adjusted logistic regression revealed no association between nerve block use and being discharged with opioids (Odds ratio (OR) 0.98, 95% CI 0.45 to 2.14, p=1.00)."

Clinical • Anesthesia • Pediatrics

Transforming Pain Management: Suzetrigine, a Novel Non-Opioid Analgesic. (PubMed, Biomol Ther (Seoul)) - "In two phase 2 clinical trials, suzetrigine demonstrated superior pain control compared to placebo and showed comparable effectiveness to hydrocodone/acetaminophen for treating moderate to severe acute pain after abdominoplasty and bunionectomy with an acceptable safety profile. Current findings support suzetrigine's potential role as a safer alternative to opioids in managing moderate to severe pain."

Journal • Addiction (Opioid and Alcohol) • Aesthetic Medicine • CNS Disorders • Depression • Pain • Psychiatry • Substance Abuse • NAV1

Postoperative Opioid Use in Pediatric Inguinal Orchiopexy. (PubMed, J Pediatr Health Care) - "In this study, we found that increasing age, lack of acetaminophen use, and preferred language of English were associated with increased postoperative opioid use. In addition, while race/ethnicity was not associated with opioid use, patient language preference for English in this Hispanic-majority population was associated with increased opioid use. The findings of this study highlight the importance of patient education and effective communication to limit opioid use and prescription."

Journal • Pain • Pediatrics

Assessing Clinician Compliance with The Office of the Inspector General (OIG) Recommended Follow-Up for Long-Term Opioid Therapy (PAINWeek 2025) - "The most common opioid initiated for long-term opioid therapy was tramadol (36.4%), followed by hydrocodone/acetaminophen (19.3%), oxycodone (18.6%), and buprenorphine (16.4%). A total of 159 patients were initially identified for review based on meeting enrollment criteria for chronic opioid therapy between July 1, 2022 to July 1, 2024. Of those patients, 5 were excluded due to off-label opioid use disorder treatment or death prior to the end of the 90-day follow-up period. Additionally, 14 patients were excluded as the prescription for the long-term opioid therapy originated from a community care provider and therefore risk mitigation strategies were not required by a VA provider."

Clinical • Compliance • Back Pain • CNS Disorders • Musculoskeletal Pain • Pain • Substance Abuse

Efficacy of Methylprednisolone for Pain Control After ACL Repair: A Randomized Controlled Trial (clinicaltrials.gov) - P4 | N=90 | Enrolling by invitation | Sponsor: St. Louis University

New P4 trial • Pain

Prescription Trends by Orthopedic Surgery Provider: Review of the Medicare Part D Prescribers - by Provider and Drug, 2013-2021. (PubMed, Orthopedics) - "In line with national guidelines, claims for NSAIDs are increasing and claims for opioid pain medications and AOMs are decreasing. Claims for outpatient antibiotics are increasing, which is of significant concern, given renewed focus on antibiotic stewardship."

Journal • Medicare • Reimbursement • Review • US reimbursement • Orthopedics • Pain

Minimal Sedation Use for Laceration Repair in the Pediatric Emergency Department. (PubMed, J Emerg Med) - "Minimal sedation agents allow for successful facial laceration repair in children and AEs were rarely reported. The quality of sedation with these agents was not studied but would be beneficial for future studies."

Journal • Anesthesia • Cardiovascular • Pediatrics

The Association of Preoperative Hydrocodone and Acetaminophen With Total Opioid Requirement, and Pain Experience in Children Undergoing Adenotonsillectomy. (PubMed, Acta Anaesthesiol Scand) - "Pre-operative hydrocodone with acetaminophen was associated with improved outcomes with respect to PACU pain experience and time to discharge. The total OME increase was limited to the pre-operative HA dose."

Journal • Retrospective data • Anesthesia • Pain • Pediatrics

The Intersection of Obesity, Testosterone Therapy, and Atrial Fibrillation: A Case Report (ENDO 2025) - "Clinical case: A 22-year-old male with a history of well-controlled diabetes mellitus (managed with Ozempic) and chronic back pain (treated with Belbuca and hydrocodone-acetaminophen) presented with palpitations and chest pain...In the emergency department, he was found to be in atrial fibrillation with Afib RVR at a heart rate of bpm, refractory to oral diltiazem but controlled with a continuous diltiazem infusion, reducing his heart rate to the 80s...Patient started on 75mg metoprolol for rate control and eliquis for stroke prevention... This case highlights the need for careful management of young patients with a complex medical history involving exogenous testosterone therapy, opioid use, and obesity. Clinicians should be vigilant in monitoring cardiovascular health and considering the risks of erythrocytosis in patients on testosterone therapy. Further research is needed to better understand the mechanisms linking hormonal therapy, erythrocytosis, and arrhythmias."

Case report • Clinical • Atrial Fibrillation • Back Pain • Cardiovascular • Diabetes • Genetic Disorders • Hematological Disorders • Infectious Disease • Metabolic Disorders • Musculoskeletal Pain • Obesity • Pain

Pharmacology Update: Suzetrigine: A Novel NaV1.8 Sodium Channel Inhibitor for Acute Pain Management. (PubMed, Am J Hosp Palliat Care) - "In Phase 2 clinical trials involving patients undergoing bunionectomy and abdominoplasty, suzetrigine achieved significant reductions in postoperative pain compared to placebo and demonstrated analgesic efficacy comparable to hydrocodone/acetaminophen. However, further research is needed to evaluate its long-term safety and efficacy, especially in chronic pain conditions and in combination with other analgesics. As its clinical use expands, suzetrigine may offer a critical tool for reducing opioid dependency across both acute and long-term pain management strategies."

Journal • Addiction (Opioid and Alcohol) • Aesthetic Medicine • Anesthesia • CNS Disorders • Depression • Neuralgia • Pain • Psychiatry • NAV1

Postoperative Pain Management in Rhinoplasty (clinicaltrials.gov) - P2 | N=130 | Active, not recruiting | Sponsor: Stanford University | Trial completion date: Jun 2025 ➔ Sep 2025

Trial completion date • Aesthetic Medicine • Pain

Rectal prolapse as a mimic of ulcerative proctitis: A diagnostic challenge (ASCRS 2025) - "Patient Background:• 87 year-old female with ulcerative colitis, scleroderma, CKD, hypothyroidism, HBP, leukopenia, and thrombocytopenia.• Previous surgeries: bilateral hip prosthesis, carpal tunnel syndrome, hysterectomy.• Medications: thyroxine, losartan, mesalazine (discontinued February 2023), mesalazine suppositories.• Allergies: acetaminophen-hydrocodone, dipyrone, hydrocortisone.2. Managing rectal prolapse in elderly patients with ulcerative proctitis requires careful consideration of overall health and comorbidities. The Delorme procedure showed promising results, with significant symptom improvement. Further studies are needed to establish best practices for similar cases, particularly in avoiding radical surgery and managing chronic inflammation effectively."

Chronic Kidney Disease • Constipation • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Gynecology • Hematological Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Leukopenia • Mucositis • Musculoskeletal Pain • Scleroderma • Systemic Sclerosis • Thrombocytopenia • Ulcerative Colitis

Limiting Narcotic Utilization Following Ankle Fracture Surgery. (PubMed, J Surg Orthop Adv) - "Patients were prescribed a multimodal pain regimen of acetaminophen, ibuprofen, gabapentin, tramadol, and two sealed envelopes each containing a prescription for 10 tablets of hydrocodone/acetaminophen 5/325 mg. This study hopes to provide a prescribing guideline that may decrease reliance on opioid analgesia. (Journal of Surgical Orthopaedic Advances 34(1):023-025, 2025)."

Journal • Retrospective data • Genetic Disorders • Musculoskeletal Diseases • Obesity • Orthopedics • Pain

Comparing Perioperative Outcomes in Pain Control (clinicaltrials.gov) - P4 | N=100 | Active, not recruiting | Sponsor: University of California, San Diego | Trial primary completion date: Dec 2023 ➔ Dec 2024

Trial primary completion date • Orthopedics • Pain

A new prescribing strategy combined with multimodal analgesics reduces unused opioid doses: a prospective observational study. (PubMed, Oral Surg Oral Med Oral Pathol Oral Radiol) - "By combining medications with anti-inflammatory properties, long-acting local anesthesia, and a unique prescribing practice, we were able to achieve satisfactory pain control and limit leftover opiate use. (Oral Surg Oral Med Oral Pathol Oral Radiol YEAR;VOL:page range)."

Journal • Observational data • Anesthesia • Pain

Drug-induced nasal septum perforation: a disproportionality analysis of the FDA adverse event reporting system database. (PubMed, Expert Opin Drug Saf) - "For 552 identified cases, the most commonly reported drugs were bevacizumab (n = 56), fluticasone propionate (n = 50), methotrexate (n = 34), hydrocodone and acetaminophen (n = 22), and paclitaxel (n = 17). Twenty-six drugs showed positive risk signals, with the top five being azelastine hydrochloride and fluticasone propionate (ROR = 173.82), beclomethasone dipropionate (ROR = 90.91), oxymetazoline (ROR = 53.77), desmopressin (ROR = 51.43), and leucovorin (ROR = 42.83). Intriguingly, 18 of these drugs did not list nasal septum perforation as a known side effect. This study provides a comprehensive overview of drug-induced nasal septum perforation from a pharmacovigilance perspective, highlighting the need for further research to clarify these associations and update drug safety information to reduce patient risk."

Adverse events • Journal

Postoperative Pain Management in Rhinoplasty (clinicaltrials.gov) - P2 | N=130 | Active, not recruiting | Sponsor: Stanford University | N=51 ➔ 130

Enrollment change • Aesthetic Medicine • Pain

Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure (clinicaltrials.gov) - P2 | N=60 | Active, not recruiting | Sponsor: Northwestern University | Recruiting ➔ Active, not recruiting | Trial completion date: Aug 2023 ➔ Jun 2025 | Trial primary completion date: Aug 2023 ➔ Jun 2025

Enrollment closed • Trial completion date • Trial primary completion date • Addiction (Opioid and Alcohol) • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain • Substance Abuse

Post-Op Pain Control for Prophylactic Intramedullary Nailing. (clinicaltrials.gov) - P3 | N=60 | Recruiting | Sponsor: St. Louis University | Trial completion date: Oct 2024 ➔ Dec 2026 | Trial primary completion date: Aug 2024 ➔ Oct 2026

Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Multiple Myeloma • Oncology • Pain • Solid Tumor